Corporate Office : Mahendra Industrial Estate.

=D
l=

ll=

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Plot No. 109-D, Road No. 29, Sion (East),

Mumbai - 400 022. (India)
fel.: 022-2407 2249 | 24Ol 9025 (30 Lines)
Fax:022-2407 3462 I 2407 0144
Email : audit@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : 137060MH1984P1C055433

Ref.: ADI"/SE/2016-17
Date: 9th November, 2016
To,
Department of Corporate Service,
BSE Ltd.
Phiroze feejeebhoy Towers,
Dalal Street, Mumbai - 400 001.
BSE CODE - 524348

To,

National Stock Exchange of India Limited,

"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release

Dear Sir/Madam,
Please

find enclosed herewith copy of the press release issued by the Company on

November,201.6.
This is for your kind information and records. Kindly acknowledge the receipt.

Thanking you,
Yours faithfully,
For Aarti Drugs Limited

Vibhav

S. Ranade

Company Secretary & Compliance Officer

Encl:A/A

Regd. office : Plot No. N-198, MIDC, Tarapur, Tal-palghar, Dist. palghar 401 so6. (MH)

9th

Corporate Office : Mahendra Industrial Estate,

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Plot No. 109-D, Road No. 29, Sion (East),

Mumbai - 400 022. (India)
Tet.i 022-2407 2249 | 24Ot 9025 (30 Lines)
Fax: 022-2407 3462 | 2407 0144
Email : audit@aaftidrugs.com
Website : www.aartidrugs.com
CIN NO : 137060MH1984P1C055433

Press release for Septl6:

September quarter has shown good demand growth both in domestic as well as global
markets. Due to lower crude prices, raw material and finished goods prices are lower as
compared to previous year. However, excellent volume growth of around 25-30% in the key
products, across various geographies, has led to the consolidated sales growth of 15.58%.
Consolidated Profit after tax for the quarter ended Sep'l6 is 22.07 crores, up by 40.46Yo due
to higher asset utilization and further reduction in interest cost. Consolidated EBITDA for
the quarter ended Sep'16 is 51.14 crores, up by 16.23%. Company was able to keep its net
operating working capital to optimum and lowered its Debt/Equity ratio to 1.1

New facility and product approvals for different markets, from the recently

expanded
capacities, have led to increased sales. Company is expecting an EDQM/European authority
audit in 4fr week of Nov'16 for the Tarapur facility. Company has invested in automation of
its quality systems, which will be helpful for future regulatory audits.

For Aarti Drugs Limited

il.
re5"n^"

Harshit M. Savla
Jt. Managing Director
DIN:00005340

Regd. office : Plot No. N-198, MIDC, Tarapur, Tal-palghar; Dist. palghar - 401 506. (MH)